Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Aug 31, 2026 to Oct 31, 2025
    • Study completion moved earlier from Dec 31, 2027 to Jul 31, 2027
    • Secondary endpoints: details revised at 4 of 8 entries
    • Eligibility criteria expanded, about 4 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 27 to confirmed 19
    • Site details revised
    v10
  3. Primary completion date: Dec 31, 2025 to Aug 31, 2026
    • Enrollment target: 24 to 27
    v9
  4. Re-verified, no change to tracked fieldsv8
  5. Trial status: Suspended to Recruiting
    • Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Study completion date: Dec 31, 2024 to Dec 31, 2027
    • Site details revised
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Trial status: Recruiting to Suspended Sponsor's reason: Per an amendment
    • Primary completion date: Dec 31, 2022 to Dec 31, 2024
    • Study completion date: Dec 31, 2023 to Dec 31, 2024
    • Site details revised
    v6
  2. Primary completion date: Dec 31, 2021 to Dec 31, 2022
    • Study completion date: Dec 31, 2021 to Dec 31, 2023
    v5
  3. Site contact updated
    • Collaborators shortened, about 4 words
    v4
  4. Eligibility criteria expanded, about 34 words
    • Study description expanded, about 3 words
    • Study title expanded, about 1 word
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 1, 2019 to Feb 7, 2019
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I trial studies the side effects and how well papaverine hydrochloride and stereotactic radiation therapy body (SBRT) work in treating patients with non-small cell lung cancer. Papaverine hydrochloride may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving papaverine hydrochloride with SBRT may work in treating patients with non-small cell lung cancer.
Trial Details
NCT Number NCT03824327
Lead Sponsor Ohio State University Comprehensive Cancer Center
Conditions
(from sponsor)		 Lung Non-Small Cell Carcinoma
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov